AnaptysBio (NASDAQ:ANAB) Shares Down 6.2% - What's Next?

Key Points

• AnaptysBio shares fell 6.2% to about $51.51 in midday trading, with volume 62% below the average session level.
• Analyst sentiment remains generally positive: 12 analysts rate the stock a Buy, three rate it Hold and one rates it Sell. The consensus rating is “Moderate Buy,” with a $79.85 price target.
• The company reported quarterly EPS of $5.11, beating estimates by $5.57, while revenue of $27.49 million exceeded the $14.06 million consensus forecast. Despite the strong quarter, analysts expect a full-year loss of $2.06 per share.

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) shares traded down 6.2% during mid-day trading on Tuesday . The company traded as low as $50.94 and last traded at $51.5080. 265,960 shares were traded during mid-day trading, a decline of 62% from the average session volume of 693,087 shares. The stock had previously closed at $54.92.

Wall Street Analyst Weigh In

ANAB has been the topic of several research analyst reports. Zacks Research lowered shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 2nd. Scotiabank lowered AnaptysBio to a "hold" rating and set a $70.00 price target on the stock. in a research note on Tuesday, August 25th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of AnaptysBio in a report on Tuesday. Wolfe Research reissued an "outperform" rating and set a $78.00 price objective on shares of AnaptysBio in a report on Monday, August 31st. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of AnaptysBio in a research note on Friday, August 7th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, AnaptysBio presently has a consensus rating of "Moderate Buy" and a consensus price target of $79.85.

AnaptysBio Stock Performance

The company has a 50-day moving average of $55.84 and a 200 day moving average of $59.26. The firm has a market cap of $1.56 billion, a P/E ratio of -48.21 and a beta of 0.71.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $5.57. The company had revenue of $27.49 million for the quarter, compared to analyst estimates of $14.06 million. During the same quarter in the prior year, the company earned ($1.30) earnings per share. Sell-side analysts anticipate that AnaptysBio, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Investors Weigh In On AnaptysBio

A number of large investors have recently bought and sold shares of the business. Persistent Asset Partners Ltd acquired a new position in AnaptysBio during the 2nd quarter worth about $39,000. Caitong International Asset Management Co. Ltd boosted its position in AnaptysBio by 940.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company's stock valued at $74,000 after buying an additional 1,383 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of AnaptysBio by 21.2% in the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company's stock valued at $79,000 after buying an additional 284 shares during the period. Group One Trading LLC bought a new stake in shares of AnaptysBio during the second quarter worth $140,000. Finally, State of Wyoming bought a new position in AnaptysBio in the second quarter valued at about $158,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company's programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio's pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.